Efficacy of dupilumab in palmoplantar pustulosis treatment highlights the role of Th2 inflammation
Abstract
Palmoplantar pustulosis is a chronic, recurrent skin disorder characterized by sterile pustules and erythematous scaling on the palms and soles. In our study, dupilumab treatment showed efficacy and safety in PPP patients, potentially resulting from PPP patients' serum Th2 signatures and the similarities between PPP and atopic dermatitis based on serum Olink proteomics.Keywords
Funding Information
- National Natural Science Foundation of China ((82373466,82073426,82230104))
This publication has 8 references indexed in Scilit:
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trialsJournal of the American Academy of Dermatology, 2023
- CCL13 and human diseasesFrontiers in Immunology, 2023
- Recalcitrant palmoplantar pustulosis controlled with dupilumabJAAD Case Reports, 2023
- Successful treatment of secukinumab‐resistant palmoplantar pustulosis by Dupilumab: A case reportDermatologic Therapy, 2022
- Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosisJournal of Allergy and Clinical Immunology, 2022
- Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging TreatmentsAmerican Journal of Clinical Dermatology, 2020
- Dermal fibroblasts from acute inflamed atopic dermatitis lesions display increased eotaxin/CCL11 responsiveness to interleukin-4 stimulationBritish Journal of Dermatology, 2011
- Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic modelJournal of Allergy and Clinical Immunology, 2006